Non-Cystic Fibrosis Bronchiectasis Pipeline Insight: Over 15 Companies are Progressing Through to Improve the Treatment Landscape | DelveInsight
The non-cystic fibrosis bronchiectasis market is driven by rising prevalence linked to respiratory infections, autoimmune diseases, and COPD. Increasing awareness among healthcare providers and ...
pharmaphorum2d
England, Denmark back CSL’s haemophilia B gene therapy
It has been a good week for CSL Behring as it rolls out haemophilia B gene therapy Hemgenix, with positive reimbursement decisions in both the UK and Denmark. In the UK, health technology ...
2 of the highest-quality blue chip ASX 200 stocks money can buy
Analysts think these blue chips are top buys for investors right now. But why? The post 2 of the highest-quality blue chip ...
Top ASX shares to buy in November with the market near all-time highs
If, like Warren Buffett, you’re struggling to find deals in this market, then here are some ASX shares our Foolish writers ...
pharmaphorum6d
Progress with the UK’s VPAG
VPAG is just the latest iteration of agreements struck between the UK government and industry. The minutes note that, whilst ...
The Australian Financial Review3d
CSL Limited
Research, development, manufacture, marketing and distribution of biopharmaceutical products and vaccines.
ncbiotech.org6d
CSL Seqirus to make bird flu vaccine in Holly Springs
CSL Seqirus is one of three healthcare businesses owned by the parent company. The other two are CSL Behring, focused on biotherapies and rare diseases, and CSL Vifor, focused on iron deficiency and ...